title: Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey.
abstract: Steroids and H(2) blockers are commonly used as supportive care for taxane-containing chemotherapy, but they also affect docetaxel's primary metabolizer, cytochrome P(450) 3A4. This retrospective observational study was performed to better understand the effects of these compounds on docetaxel-induced skin toxicities, specifically hand-foot syndrome (HFS) and facial erythema (FE), a relationship that is currently poorly understood. Member institutions of the Japan Breast Cancer Research Group were invited to complete a questionnaire on the occurrence of grade 2 or higher HFS and FE among patients treated between April 2007 and March 2008 with docetaxel as an adjuvant or neoadjuvant chemotherapeutic treatment for breast cancer. We obtained data for 993 patients from 20 institutions. Twenty percent received H(2) blockers, and all patients received dexamethasone. Univariate and multivariate analyses revealed that H(2) blockers are associated with a significantly higher incidence of both HFS and FE. The incidence of FE was significantly higher for the docetaxel + cyclophosphamide (TC) regimen than for non-TC regimens combined. Dexamethasone usage did not affect the incidence of either HFS or FE. In conclusion, use of H(2) blockers as premedication in breast cancer patients receiving docetaxel significantly increases the risk of both HFS and FE.
authors.affiliation: Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kawaguchi
authors.forename: H
authors.initials: H
authors.lastname: Ishiguro
authors.forename: S
authors.initials: S
authors.lastname: Morita
authors.forename: S
authors.initials: S
authors.lastname: Nakamura
authors.forename: S
authors.initials: S
authors.lastname: Ohno
authors.forename: N
authors.initials: N
authors.lastname: Masuda
authors.forename: H
authors.initials: H
authors.lastname: Iwata
authors.forename: K
authors.initials: K
authors.lastname: Aogi
authors.forename: K
authors.initials: K
authors.lastname: Kuroi
authors.forename: M
authors.initials: M
authors.lastname: Toi
mesh_terms: D000081:Acetamides / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003907:Dexamethasone / Q000627:therapeutic use*; D000077143:Docetaxel; D004890:Erythema / Q000453:epidemiology / Q000209:etiology*; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D060831:Hand-Foot Syndrome / Q000453:epidemiology / Q000209:etiology*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D015999:Multivariate Analysis; D020360:Neoadjuvant Therapy / Q000009:adverse effects; D010880:Piperidines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011899:Ranitidine / Q000627:therapeutic use; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D043823:Taxoids / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000081:Acetamides; D005938:Glucocorticoids; D006635:Histamine H2 Antagonists; D010880:Piperidines; D011725:Pyridines; D013256:Steroids; D043823:Taxoids; D000077143:Docetaxel; C076948:lafutidine; D015738:Famotidine; D003907:Dexamethasone; D011899:Ranitidine